HOME >> MEDICINE >> NEWS
Studying the fate of drugs in wastewater

Researchers at the National Institute of Standards and Technology (NIST) have published an interesting study that sheds light on the fate of a familiar pharmaceutical as it enters the waste stream. In work initially described last year, NIST chemists investigated probable chemical reactions involving acetaminophen when the drug is subjected to typical wastewater processing. Acetaminophen is the most widely used pain reliever in the United States, and a study of 139 streams by the U.S. Geological Survey found that it was one of the most frequently detected man-made chemicals.

The scientists found that the drug readily reacts in chlorine disinfection to form at least 11 new products, at least two of which are known to be toxic. The results, according to lead author Mary Bedner, demonstrate that environmental scientists need to be concerned about downstream reaction products as well as the original waste materials. "The issue is what you should be looking for in the environment," she says. "When you are looking for the effects of pharmaceuticals in the environment, you need to ask what they're going to turn into."


'"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
23-Dec-2005


Page: 1

Related medicine news :

1. Studying brain activity could aid diagnosis of social phobia
2. UIC researchers to develop new drugs to fight bioterrorism
3. Statin drugs may delay progressive artery damage in children
4. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
5. Experts call for urgent research into anti-epileptic drugs given to children
6. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Antipsychotic drugs increase risk of death in older people with dementia
9. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
10. Panel offers guidelines on skin reactions to new class of cancer drugs
11. Blood-thinning drugs need closer monitoring

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Studying the fate drugs wastewater

(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since ... acknowledged September 26th as Mesothelioma Awareness Day . On this day, and in ... several ways of becoming involved and helping the cause. , “One of the ways ...
(Date:8/31/2015)... ... , ... MeYou Health ®, a social well-being company and wholly owned ... by including an in-app step tracker. , Walkadoo is a pedometer-based walking program ... than broadly assign every Walkadoo member 10,000 steps a day (as is typical for ...
(Date:8/31/2015)... ... ... It’s a lot like coming home. Life-long Fox Valley resident James Holbrook has ... on the job, he’s run into residents of the retirement community who he’s known ... living in such a wonderful place,” he said. GreenFields, which is sponsored by Friendship ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted ... Owners and provided a tour of their North American facility following the S.M.A.R.T ... international companies expanding business in the U.S. , The PartnerTech Inc. North ...
(Date:8/31/2015)... Dallas, TX (PRWEB) , ... August 31, 2015 ... ... Coalition’s EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on ... building. The eye-catching campaign image is designed to inspire and promote earlier awareness ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:PartnerTech Supports Economic Growth as Host 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
Cached News: